Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis

被引:13
|
作者
Melcon-Fernandez, Estela [1 ]
Galli, Giulio [1 ]
Garcia-Estrada, Carlos [1 ]
Balana-Fouce, Rafael [1 ]
Reguera, Rosa M. [1 ]
Perez-Pertejo, Yolanda [1 ]
机构
[1] Univ Leon, Dept Ciencias Biomed, Campus Vegazana S-N PC, Leon 24071, Spain
关键词
Leishmania; drug combinations; nifuratel; miltefosine; drug repurposing; DRUG-RESISTANCE; AMPHOTERICIN-B; KALA-AZAR; REDUCTASE; INHIBITORS; DESIGN; CHEMOTHERAPY; DERIVATIVES; EFFICACY; NEPAL;
D O I
10.3390/ijms24021635
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Visceral leishmaniasis is a neglected vector-borne tropical disease caused by Leishmania donovani and Leishmania infantum that is endemic not only in East African countries, but also in Asia, regions of South America and the Mediterranean Basin. For the pharmacological control of this disease, there is a limited number of old and, in general, poorly adherent drugs, with a multitude of adverse effects and low oral bioavailability, which favor the emergence of resistant pathogens. Pentavalent antimonials are the first-line drugs, but due to their misuse, resistant Leishmania strains have emerged worldwide. Although these drugs have saved many lives, it is recommended to reduce their use as much as possible and replace them with novel and more friendly drugs. From a commercial collection of anti-infective drugs, we have recently identified nifuratel-a nitrofurantoin used against vaginal infections-as a promising repurposing drug against a mouse model of visceral leishmaniasis. In the present work, we have tested combinations of miltefosine-the only oral drug currently used against leishmaniasis-with nifuratel in different proportions, both in axenic amastigotes from bone marrow and in intracellular amastigotes from infected Balb/c mouse spleen macrophages, finding a potent synergy in both cases. In vivo evaluation of oral miltefosine/nifuratel combinations using a bioimaging platform has revealed the potential of these combinations for the treatment of this disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Effectivity and safety of miltefosine used for the treatment of visceral leishmaniasis
    Fernandez-Redondo, D.
    Caro-Teller, J. M.
    Nieves-Sedano, M.
    Lazaro-Cebas, A.
    Pablos-Bravo, S.
    Gomez-Valbuena, I.
    Alioto, D.
    Ferrari-Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 581 - 582
  • [32] Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
    Nogueira, Fabio dos Santos
    Avino, Valdir Carlos
    Galvis-Ovallos, Fredy
    Pereira-Chioccola, Vera Lucia
    Batistella Moreira, Marcio Antonio
    Peres Lopes Romariz, Ana Paula
    Molla, Leticia M.
    Menz, Ingrid
    PARASITES & VECTORS, 2019, 12
  • [33] Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis
    Jha, TK
    Sundar, S
    Thakur, CP
    Bachmann, P
    Karbwang, J
    Fischer, C
    Voss, A
    Berman, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24): : 1795 - 1800
  • [34] Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
    Fabio dos Santos Nogueira
    Valdir Carlos Avino
    Fredy Galvis-Ovallos
    Vera Lucia Pereira-Chioccola
    Marcio Antonio Batistella Moreira
    Ana Paula Peres Lopes Romariz
    Leticia M. Molla
    Ingrid Menz
    Parasites & Vectors, 12
  • [35] Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
    Bhandari, Vasundhra
    Kulshrestha, Arpita
    Deep, Deepak Kumar
    Stark, Olivia
    Prajapati, Vijay Kumar
    Ramesh, V.
    Sundar, Shyam
    Schonian, Gabriele
    Dujardin, Jean Claude
    Salotra, Poonam
    PLOS NEGLECTED TROPICAL DISEASES, 2012, 6 (05):
  • [36] Combination therapy for visceral leishmaniasis
    van Griensven, Johan
    Boelaert, Marleen
    LANCET, 2011, 377 (9764): : 443 - 444
  • [37] Combination therapy for visceral leishmaniasis
    van Griensven, Johan
    Balasegaram, Manica
    Meheus, Filip
    Alvar, Jorge
    Lynen, Lutgarde
    Boelaert, Marleen
    LANCET INFECTIOUS DISEASES, 2010, 10 (03): : 184 - 194
  • [38] The pentamidine-miltefosine combination as an alternative to liposomal amphotericin B for treating Leishmania infantum visceral leishmaniasis in the immunodeficient host
    Faucher, J. -F.
    Morquin, D.
    Reynes, J.
    Hoen, B.
    Le Moing, V.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2013, 18 : 135 - 135
  • [39] Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis
    Al-Abdely, HM
    Graybill, JR
    Bocanegra, R
    Najvar, L
    Montalbo, E
    Regen, SL
    Melby, PC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) : 2542 - 2548
  • [40] Decreased miltefosine susceptibility in clinical isolates of Leishmania donovani derived from visceral leishmaniasis and post kala-azar dermal leishmaniasis: Apparent mechanisms and clinical implications
    Singh, R.
    Deep, D. K.
    Bhandari, V.
    Sharma, V.
    Negi, N. S.
    Ramesh, V.
    Salotra, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 381 - 381